What is PeptiCRAd

PeptiCRAd

PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) is an innovative and unique way of combining two clinically proven cancer immunotherapy approaches: an oncolytic Adenovirus and a peptide vaccine, to take advantage of the best features of both technologies. The idea is straightforward: to use immunogenic viruses as active carriers of tumor-specific peptides to direct the immune system to specifically target and kill cancer cells.

Oncolytic Adenovirus

  • - Tumor-specific replication
  • - Immune-boosting modifications
  • - Tumor-targeting modifications

Tumor-specific Peptides

MHC-I Peptide

Poly-lysine

  • - Clinically proven vaccine peptides
  • - Novel tumor peptides
  • - Unique patient-specific neoantigens

Patient-specific Treatment

PeptiCRAd

  • - Multiple different tumor-specific peptides can be adsorbed onto one PeptiCRAd
  • - Multiple tumor-specific antigens can be targeted simultaneously

PeptiCRAd is an oncolytic adenovirus platform, where immunogenic tumor peptides are adsorbed onto the negatively charged viral capsid

1Immune response against PeptiCRAd-loaded tumor peptides

Following intratumoral PeptiCRAd administration, PeptiCRAd is taken up by antigen presenting cells (APCs). PeptiCRAd triggers activation of APCs via multiple pathogen recognition receptor (PRR) mediated pathways. APCs process peptides and present them on MHC-1 molecules. In the draining lymph node, activated APCs present peptides to naive CD8+ T-cells.

2Immune response against patient-specific unique tumor antigens

PeptiCRAd replication causes tumor cell lysis and release of tumor associated antigens (TAAs). Danger signals from dying tumor cells activate APCs. APCs take up TAAs and present them on MHC-1 molecules. In the draining lymph node, activated APCs present TAAs to naive CD8+ T-cells

3Systemic CD8+ T-cell mediated immune attack against tumors

Local PeptiCRAd treatment initiates a robust systemic CD8+ T-cell immunity against virus-loaded tumor peptides as well as multiple unique patient-specific tumor antigens.